Atea Pharmaceuticals(NASDAQ) AVIR

Atea Pharmaceuticals creates oral pills to treat serious viral infections like hepatitis. The company focuses on helping patients whose immune systems cannot easily fight off diseases. These medications aim to block viruses from replicating inside the human body.

Focusing on Liver Health

• Hepatitis C Therapy: A combined regimen of bemnifosbuvir and ruzasvir designed to treat all major types of the virus in a short time.
• Hepatitis E Treatment: An experimental drug called AT-587 being developed for high-risk patients with weak immune systems.
• Direct-Acting Antivirals: Oral medications that target specific enzymes to stop a virus from copying its genetic material.

Key Deals and Trial Steps

• Partnered with Merck & Co, Inc. in December 2021 to develop and sell ruzasvir globally.
• Started the C-BEYOND and C-FORWARD Phase 3 clinical trials in 2025 to test a new liver disease treatment.
• Ended the development of a treatment for COVID-19 in September 2024 following clinical trial outcomes.

Engineering Better Antivirals

The company uses a proprietary platform to build synthetic molecules that mimic natural genetic building blocks. These molecules trick viruses into using them during replication, which effectively breaks the viral life cycle.

A Look at the Numbers

• Net loss reached $44.9 million in Q4 2025, worsened 33.8% from $33.5 million in Q4 2024.
• Operating income was -$54.9 million in Q4 2025, worsened 40.8% from -$39 million in Q4 2024.
• Operating cash flow reached -$28.2 million in Q4 2025, improved 7.2% from -$30.4 million in Q4 2024.
• Revenue remained at $0 in Q4 2025 as the company has no approved products for sale yet.

The Path Forward

Atea has transitioned its focus from pandemic response to the development of specialized liver disease treatments. The company's progress now relies on the successful completion of its late-stage clinical trials for hepatitis C.